卫光生物(002880) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥280,968,618.02, representing a 40.41% increase year-over-year[4] - Net profit attributable to shareholders was ¥67,712,645.79, up 55.76% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥65,593,312.17, reflecting a 57.66% increase year-over-year[4] - Total revenue for the third quarter of 2021 was CNY 616,756,759.63, compared to CNY 607,659,905.15 in the same period of 2020, representing a year-over-year increase of approximately 1.8%[27] - Net profit for Q3 2021 reached 137,229,657.84 CNY, up from 120,328,073.29 CNY in Q3 2020, indicating an increase of about 14.1%[32] - Operating profit for Q3 2021 was 157,918,655.46 CNY, compared to 143,844,697.29 CNY in Q3 2020, marking an increase of about 9.3%[30] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,904,958,819.16, a 3.75% increase from the end of the previous year[7] - Total assets amounted to CNY 1,904,958,819.16 as of September 30, 2021, compared to CNY 1,836,144,030.49 at the end of 2020, showing an increase of approximately 3.7%[25] - Total liabilities decreased to CNY 184,446,406.65 from CNY 212,361,275.82, indicating a reduction of about 13.1% year-over-year[25] - The company’s investment in Guangzhou Hanteng Biotechnology Co., Ltd. led to a 234.72% increase in other non-current financial assets[9] Shareholder Equity - Shareholders' equity attributable to the company reached ¥1,700,961,514.72, marking a 6.06% increase from the previous year[7] - The company's equity attributable to shareholders increased to CNY 1,700,961,514.72 from CNY 1,603,788,839.86, reflecting a growth of approximately 6.1%[25] - The number of common shareholders at the end of the reporting period was not specified, but the top ten shareholders held a significant portion of shares, with the largest shareholder owning 65.25%[16] Cash Flow - Cash flow from operating activities showed a net decrease of 43.42% year-over-year, totaling ¥120,331,844.55[4] - Cash flow from operating activities for Q3 2021 was 120,331,844.55 CNY, a significant decrease from 212,679,086.22 CNY in Q3 2020, indicating a decline of about 43.3%[36] - The company reported a 40.59% decrease in cash and cash equivalents compared to the end of the previous year, primarily due to repayment of short-term loans[9] - Cash and cash equivalents decreased to CNY 280,102,189.58 as of September 30, 2021, down from CNY 471,468,969.66 at the end of 2020, indicating a decline of about 40.5%[19] - The net increase in cash and cash equivalents was -$191,366,780.08, compared to a positive increase of $161,809,959.17 previously[40] - The ending balance of cash and cash equivalents was $280,008,234.42, down from $466,416,331.35 at the end of the previous period[40] Expenses and Costs - Total operating costs for Q3 2021 were 463,900,624.08 CNY, slightly lower than 471,806,550.33 CNY in Q3 2020, showing a decrease of approximately 1.9%[30] - Research and development expenses increased to 34,650,925.82 CNY in Q3 2021, compared to 28,649,770.30 CNY in Q3 2020, reflecting a growth of approximately 21%[30] - The company's tax expenses for Q3 2021 were 20,385,987.71 CNY, down from 22,339,569.18 CNY in Q3 2020, reflecting a decrease of about 8.8%[30] Other Financial Metrics - The company’s basic earnings per share for Q3 2021 was ¥0.2986, a 10.59% increase year-over-year[4] - The company reported a basic earnings per share of 0.6070 CNY for Q3 2021, down from 0.7428 CNY in Q3 2020, representing a decrease of approximately 18.2%[33] - The company experienced a 320.25% increase in credit impairment losses compared to the same period last year, mainly due to increased provisions for bad debts[12] - Other income for Q3 2021 was reported at 7,555,275.50 CNY, compared to 6,797,290.61 CNY in Q3 2020, indicating an increase of approximately 11.2%[30] Investment Activities - Investment activities cash outflow totaled $213,160,067.70, compared to $119,360,636.14 in the previous period, indicating a significant increase[40] - Net cash flow from investment activities was -$213,125,767.70, worsening from -$118,903,374.34 year-over-year[40] Financing Activities - Cash inflow from financing activities was $75,000,000.00, down from $260,000,000.00 in the previous period[40] - Cash outflow from financing activities amounted to $173,572,856.93, compared to $191,965,752.71 previously, showing a decrease[40] - Net cash flow from financing activities was -$98,572,856.93, contrasting with a positive $68,034,247.29 in the prior period[40] Audit Status - The third quarter report was not audited, indicating potential limitations in the reliability of the financial data presented[41]